Condition

Bipolar I Disorder

ClinicalTrials.gov condition label

Clinical trials42

Recruiting7

Common interventions25

Lead sponsors shown15

Clinical trials

42 shown

Multicenter Study to Assess the Efficacy and Safety of LB-102 in the Treatment of Adult Patients With BP1MDE.NCT07494305 · 2026-01-23

Individualized Pharmacological Approach to Obesity in Patients With Bipolar DisorderNCT07213466 · 2026-01-19

Pharmacokinetics, Safety, Tolerability and Efficacy of a Subcutaneous Long-Acting Injection of Cariprazine (Cariprazine Depot) in Subjects Eligible for Treatment With Oral CariprazineNCT07185815 · 2025-08-01

LHC-CIDI-5 in Hong KongNCT06804525 · 2025-01-18

Ketogenic and Nutritional Interventions for First Episode Bipolar DisorderNCT06221852 · 2024-03-12

Safety and Tolerability of Open-Labeled Iloperidone in AdolescentsNCT05648591 · 2023-05-24

Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I DisorderNCT05303064 · 2022-06-30

Assessment of Acute Psychomotor Agitation Measures Associated With Schizophrenia and Bipolar DisorderNCT07116694 · 2025-06-19

Open Label Extension Study of NCT06221852NCT06558201 · 2024-08-28

ENROLLING_BY_INVITATION

Pharmacokinetic Study of VHX-896 and Iloperidone Tablets Under Steady-State ConditionsNCT06494397 · 2024-07-11

Study to Assess Accuracy of Rapid Mood Screener in Adult Participants With Unipolar Major Depressive Disorder or Bipolar 1 Disorder in Real World SettingNCT05956483 · 2023-12-04

A Trial to Assess a Wearable Patch's Functioning to Detect Medication IngestionNCT06372210 · 2023-06-26

Impact of a Ketogenic Diet on Metabolic and Psychiatric Health in Patients With Bipolar IllnessNCT05705063 · 2023-01-30

Dexmedetomidine in the Treatment of Agitation Associated With Schizophrenia and Bipolar Disorder (SERENITY III)NCT05658510 · 2022-11-21

Gabapentin for Restoring GABA/Glutamate Homeostasis in Co-occurring Bipolar and Cannabis Use DisordersNCT05064319 · 2022-02-24

Aripiprazole Once-Monthly in Hospitalized Patients (INITIATE)NCT04907279 · 2021-11-01

Long-term Safety Extension Study of OLZ/SAM in Pediatric SubjectsNCT04987229 · 2021-10-22

ENROLLING_BY_INVITATION

Naturalistic Study of Ketamine in the Treatment of DepressionNCT05249309 · 2021-05-01

Open-Label, Flexible-dose Study to Evaluate the Long-Term Safety and Tolerability of Cariprazine in the Treatment of Pediatric Participants With Schizophrenia, Bipolar I Disorder, or Autism Spectrum DisorderNCT04578756 · 2021-02-01

Early Psychosis Intervention - Spreading Evidence-based TreatmentNCT03919760 · 2020-01-03

Evaluating a New Iloperidone Titration Scheme in Bipolar I Disorder or SchizophreniaNCT04127058 · 2019-10-07

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic DisordersNCT03943537 · 2019-10-01

A Trial of Multiple-doses of Aripiprazole in Adults With Schizophrenia or Bipolar 1 DisorderNCT04030143 · 2019-08-01

A Trial of Single- and Multiple-doses of Aripiprazole in Adult Subjects With Schizophrenia or Bipolar I DisorderNCT03854409 · 2019-01-31

Multicenter, Randomized, Comparative and Prospective Study Evaluating the Impact on the Care Path of an Editorial Program Accompanied by Advance Directives in Psychiatry (DAP) for People Suffering From Schizophrenia, Bipolar I Disorder or Schizoaffective DisorderNCT03630822 · 2019-01-02

ERG Components in Schizophrenia and Bipolar Disorder Type INCT03788811 · 2018-07-05

ACTIVE_NOT_RECRUITING

Financial Incentives to Improve Acceptance of Antipsychotic InjectionsNCT03192631 · 2017-07-01

Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831NCT03201757 · 2017-06-15

Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I DisorderNCT03187769 · 2017-06-08

The BIO-K Study: A Single-Arm, Open-Label, Biomarker Development Clinical Trial of Ketamine for Non-Psychotic Unipolar Major Depression and Bipolar I or II Depression.NCT03156504 · 2017-06-01

Exploratory Trial to Assess the Functionality of an Integrated Call Center for the Digital Medicine SystemNCT02722967 · 2016-03-01

Effect of Ketamine vs. Active Placebo on Suicidal Ideation in Depressed Inpatients With Major Depressive Disorder or Bipolar Depression.NCT02593643 · 2016-01-01

Emotional Intelligence in Schizophrenia and Bipolar-I- DisorderNCT01998516 · 2013-12-01

Lifestyle Intervention for Diabetes and Weight Management in PsychosisNCT01828931 · 2012-12-01

Study of Lurasidone in Treating Antipsychotic Naive or Quasi-Naive Children and AdolescentsNCT01731119 · 2012-12-01

A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Sublingual Asenapine in a Pediatric Population With Schizophrenia or Bipolar I Disorder (P06522 AM1)NCT01206517 · 2010-07-18

Prevention of Weight Gain in Early PsychosesNCT01075295 · 2010-02-01

Study in Adolescents With Schizophrenia or Bipolar DisorderNCT00982020 · 2009-09-01

Trial Comparing the Effects of Aripiprazole With Those of Standard of Care on Non-HDL Cholesterol in Patients With Schizophrenia or Bipolar I Disorder Who Have Metabolic SyndromeNCT00857818 · 2009-04-01

Efficacy and Tolerability Study of Betahistine to Ameliorate Antipsychotic Associated Weight GainNCT00709202 · 2008-07-01

Quetiapine Fumarate (SEROQUEL) in the Treatment of Adolescent Patients With Schizophrenia and Bipolar I DisorderNCT00227305 · 2004-08-01

A Study of Aripiprazole in Patients With Bipolar I Disorder With a Major Depressive EpisodeNCT00094432 · 2004-06-01

Common interventions

Leading sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.6 Alkermes, Inc.4 Centre for Addiction and Mental Health3 Mclean Hospital3 Vanda Pharmaceuticals3 AbbVie2 BioXcel Therapeutics Inc2 Mayo Clinic2 Assistance Publique Hopitaux De Marseille1 AstraZeneca1 diaMentis Inc.1 Eli Lilly and Company1 Focus Community Mental Health Team1 Hospital de Clinicas de Porto Alegre1 LB Pharmaceuticals Inc.1

Trial status mix

COMPLETED27

RECRUITING7

UNKNOWN4

ENROLLING_BY_INVITATION2

ACTIVE_NOT_RECRUITING1

TERMINATED1

Phase mix

NA9

PHASE29

PHASE39

PHASE16

PHASE44

EARLY_PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.